In the initial report of the RIGENERA (“Recupero dall’Infarto miocardico con G-CSF E Nuovi Esempi di Rigenerazione Avanzata”) study, we reported a significant 5% increase in left ventricular ejection fraction (LVEF), in the absence of echocardiographic signs of ventricular dilatation in patients treated by G-CSF at 6-month follow-up, which was not observed in patients randomized to placebo [5]. The gene discussed is CSF3; the disease is Ventriculomegaly.